Alternative Antidepressant Options

Introduction to Alternative Antidepressants

For patients who cannot take SSRIs, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or bupropion are suitable alternative antidepressant options, with the specific choice depending on the patient's symptoms and comorbidities 1

Duloxetine: Starting dose 20-30mg once daily, increasing to target dose of 60mg daily 1
Tricyclic antidepressants: Start with low doses (10-25mg) at bedtime and titrate slowly, targeting doses of 50-150mg daily 2

For depression with anxiety, first choice is SNRIs (venlafaxine or duloxetine), and second choice is TCAs (nortriptyline or desipramine) 1
For depression with pain syndromes, first choice is Duloxetine (particularly for neuropathic pain), and second choice is TCAs (amitriptyline or nortriptyline) 1
For depression with fatigue/low energy, first choice is Bupropion, and second choice is Venlafaxine (higher doses) 1
For depression with insomnia, first choice is Mirtazapine (15-45mg at bedtime), and second choice is TCAs (particularly amitriptyline) 1
For depression with cardiac issues, first choice is Bupropion (with cardiac monitoring), and second choice is SNRIs (with blood pressure monitoring), and avoid TCAs (especially tertiary amines like amitriptyline) 1

For SNRIs, monitor blood pressure, particularly with venlafaxine at doses >150mg daily 1
For Bupropion, monitor for insomnia, agitation, seizure risk (keep doses ≤400mg/day) 1
For TCAs, monitor for dry mouth, sedation, constipation, and orthostatic hypotension, and avoid in patients with cardiac conduction abnormalities 3

Venlafaxine + bupropion has shown efficacy in treatment-resistant depression, allow 4-6 weeks at therapeutic doses before considering a medication ineffective 1

Approximately 25% of patients will achieve remission after switching to another antidepressant following SSRI failure, so persistence with finding the right medication is important 1
The American Gastroenterological Association recommends TCAs for treating irritable bowel syndrome and other conditions with anxiety components, while SSRIs are specifically recommended against due to low certainty in evidence and potential worsening of symptoms (RR, 0.74; 95% CI, 0.52–1.06) 3, 2
TCAs demonstrate global symptom relief (RR, 0.67; 95% CI, 0.54–0.82) and abdominal pain relief (RR, 0.76–0.94) in anxiety-related conditions, and have multiple mechanisms of action, including inhibition of serotonin and noradrenergic reuptake plus blockade of muscarinic, adrenergic, and histamine receptors 3, 2
Pregabalin may be considered for anxiety with neuropathic pain components 4
Avoid abrupt discontinuation of benzodiazepines when transitioning to TCAs; implement a gradual taper over several weeks, and do not combine TCAs with MAOIs due to risk of serotonin syndrome 4, 5